Palbociclib (3 in Figure 2) is a pyrido[2,3-d]pyrimidin-7-one and is a type I CDK 4/6 selective inhibitor by Pfizer, approved in 2017 for the treatment of HR-positive and HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.